Key Research Findings
- 01FDA-approved as Egrifta — one of few research peptides with clinical approval
- 02Stimulates endogenous GH release via pituitary GHRH receptors
- 03Studied for visceral fat reduction — primary approved indication
- 04Research shows improvements in IGF-1 levels and body composition
- 05Investigated for cognitive benefits including memory and executive function
- 06More physiological GH release pattern versus exogenous GH administration
Research Use Disclaimer: All information presented is for educational and research purposes only. Peptide Atelier products are intended for legitimate scientific research by qualified researchers. These products are not intended for human consumption, veterinary use, or diagnostic purposes. Always consult relevant literature and comply with applicable regulations in your jurisdiction.